Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-5G: Pegfilgrastim vs Filgrastim for Bone Pain in Breast Cancer
NCT04781959Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in febrile neutropenia (FN) comparing 5 Days of Filgrastim with Pegfilgrastim (2 arms). Primary endpoint: Bone pain at 5 days. Started Jun 2021; status: completed.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT04781959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781959.